ARCHIVES

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Cholesterol-Lowering Drugs May Prevent Breast Cancer

October 31, 2003

NCAB Subcommittee Calls For Review Of Organ Site Program, Consideration Of One For Lung Cancer

May 1, 1981

Conversation with The Cancer Letter: Pat White: NIH Funding “Our Only Concern”

September 26, 2014

“The One Thing You Want From AN NCI Director: He Will Be Bound By The Facts”

October 28, 1994

Neulasta Reduces Incidence Of Febrile Neutropenia

February 22, 2013

ACS Says NCI Needs $1.1 Billion, Cites Progress In Prevention, Control

April 29, 1977